Tadalafil’s benefits mean it’s a popular choice for doctors to prescribe for men when treating erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. This medicine is a phosphodiesterase type 5 (PDE5) inhibitor and has changed how millions of men manage these conditions.
The FDA has approved tadalafil for use when prescribed by a doctor; you may have heard of it under brand names like Cialis and Adcirca.
What is Tadalafil?
Tadalafil is part of a class called PDE5 inhibitors. It blocks the phosphodiesterase type 5 enzyme that controls blood flow in the body. Blocking this enzyme increases blood circulation to certain areas, which makes tadalafil useful in several treatments.
How Tadalafil Works
Tadalafil operates through several distinct mechanisms that all successfully contribute to its therapeutic effects:
Inhibition of PDE5 Enzyme: Tadalafil selectively inhibits phosphodiesterase type 5, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP). By preventing cGMP breakdown, tadalafil allows for increased levels of cGMP in smooth muscle cells, leading to smooth muscle relaxation and vasodilation.¹
Enhancement of Nitric Oxide Signalling: The increased cGMP levels amplify the effects of nitric oxide that are released during sexual stimulation; this results in improved blood flow to the corpus cavernosum of the penis and therefore helps to facilitate an erection.²
Smooth Muscle Relaxation: Tadalafil’s PDE5 inhibition affects smooth muscle in the prostate and bladder neck. Relaxing these muscles reduces urinary symptoms associated with benign prostatic hyperplasia.³
Pulmonary Vasodilation: In pulmonary arteries, PDE5 inhibition leads to vasodilation and reduced pulmonary arterial pressure, which is beneficial in treating pulmonary arterial hypertension.⁴
Tadalafil Benefits and Clinical Applications
Erectile Dysfunction
Tadalafil demonstrates exceptional efficacy for treating erectile dysfunction. A comprehensive meta-analysis demonstrated that tadalafil significantly improved erectile function scores compared to placebo, with efficacy rates ranging from 60-81% depending on dosage.⁵
What sets tadalafil apart completely from other treatments is that its effects last for up to 36 hours. This allows for greater spontaneity and flexibility in intimate situations.
Benign Prostatic Hyperplasia
Tadalafil alleviates lower urinary tract symptoms associated with BPH by relaxing smooth muscle in the prostate and bladder. A large-scale randomised controlled trial involving 1,058 men demonstrated that taking 5mg of tadalafil daily improved International Prostate Symptom Scores by an average of 2.6 points compared to placebo after 12 weeks of treatment.⁶
Combined Erectile Dysfunction and Benign Prostatic Hyperplasia Treatment
For men who experience both erectile dysfunction and benign prostatic hyperplasia, tadalafil provides dual benefits. A randomised trial established that daily use of tadalafil improved both erectile function and BPH symptoms simultaneously, with 71% of patients reporting improved erectile function.⁷
Pulmonary Arterial Hypertension
Tadalafil is FDA-approved for PAH treatment at higher doses (40 mg daily). A pivotal trial showed that tadalafil improved exercise capacity by an average of 33 meters in a six-minute walk test compared to placebo, along with improvements in PAH symptoms and haemodynamics.⁸
Tadalafil vs Other PDE5 Inhibitors
Tadalafil differs from sildenafil (Viagra) and vardenafil in several key ways:
Duration of Action: Tadalafil’s 17.5-hour half-life provides up to 36 hours of therapeutic effect, compared to 4-5 hours for sildenafil and vardenafil. This extended duration allows for greater spontaneity and the option for daily low-dose administration.⁹
Food Interactions: Unlike sildenafil, tadalafil absorption is minimally affected by food intake, providing more flexibility in administration timing.
BPH Indication: Tadalafil is the only PDE5 inhibitor approved for the treatment of BPH, either alone or in combination with ED, making it the perfect treatment option for men who experience both conditions.
Potential Side Effects
Tadalafil is generally a gentle treatment and tends to be well-tolerated by users, however, it is important to have it prescribed and monitored by healthcare professionals.
Common side effects include:
- Headache (11-15% of users)
- Dyspepsia (10-12%)
- Back pain (6-12%)
- Myalgia (3-6%)
- Nasal congestion (3-4%)
- Flushing (2-3%)¹⁰
Contraindications: Tadalafil is contraindicated in patients taking nitrates or nitric oxide donors due to risk of severe hypotension.
Vision Concerns: May cause sudden vision loss in rare cases (non-arteritic anterior ischaemic optic neuropathy).
Priapism Risk: Can result in priapism (prolonged erection), requiring immediate medical attention.
Cardiovascular Considerations: Should be used cautiously in patients with cardiovascular disease.
Drug Interactions: May interact with alpha-blockers, causing symptomatic hypotension.
Conclusion
Tadalafil is a highly effective, FDA-approved treatment option for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension when prescribed by a qualified healthcare professional. Tadalafil benefits men who want a treatment that can feel natural, with minimal interruption to their daily life. Its extended duration of action, minimal side effects, and dual therapeutic benefits make it a preferred choice for many patients.
UK Sarms sell tadalifil for research purposes only. The information provided in this article does not constitute medical advice, and we always recommend consulting with a medical professional.
References
- Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274(20):13729-32. PMID: 10318772.
- Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8(2):47-52. PMID: 8858389.
- Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917-25. PMID: 22297243.
- Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-903. PMID: 19470885.
- Yuan J, Zhang R, Yang Z, Lee J, Liu Y, Tian J, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902-12. PMID: 23395275.
- Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008;180(4):1228-34. PMID: 18722631.
- Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012;9(1):271-81. PMID: 22082303.
- Oudiz RJ, Brundage BH, Galiè N, Ghofrani HA, Simonneau G, Botros FT, et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768-74. PMID: 22818063.
- Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50(2):351-9. PMID: 16530932.
- Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005;96(3):257-80. PMID: 16042711.